Form 4: FibroBiologics Director Niklas Victoria Ninon Olivia Acquires Stock Options
SEC Form 4 Filing
Director Niklas Victoria Ninon Olivia reports acquisition of stock options in FibroBiologics, Inc.
Summary
- On August 27, 2024, Niklas Victoria Ninon Olivia, a director of FibroBiologics, Inc. (FBLG), reported the acquisition of 5,000 stock options.
- The options have an exercise price of $1.73.
- The options vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.
- The options expire on August 26, 2034.
- Following the transaction, Olivia directly owns 5,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, reporting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 08/27/2024 | Date of transaction: Niklas Victoria Ninon Olivia acquired stock options. |
| 08/26/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.